Reference(s)
Click here to return to the Reference Table

Category: Carcinomas
Cancer type: Bladder
Descriptor: Therapeutic Development


Reference Number: 549
Koga F, Tsutsumi S, Neckers LM. Low dose geldanamycin inhibits hepatocyte growth factor and hypoxia-stimulated invasion of cancer cells. Cell Cycle. 6, 1393-402 (2007)
PubMed link      E-mail link

Reference Number: 715
Arena S, Pisacane A, Mazzone M, Comoglio PM, Bardelli A. Genetic targeting of the kinase activity of the Met receptor in cancer cells. Proc Natl Acad Sci U S A. 104, 11412-7 (2007)
PubMed link      E-mail link

Reference Number: 853
Bhuvaneswari R, Gan YY, Lucky SS, Chin WW, Ali SM, Soo KC, Olivo M. Molecular profiling of angiogenesis in hypericin mediated photodynamic therapy. Mol Cancer. 7, 56 (2008)
PubMed link      E-mail link

Reference Number: 1183
Sun B, Liu R, Xiao ZD, Zhu X. c-MET protects breast cancer cells from apoptosis induced by sodium butyrate. PLoS One. 7, e30143 (2012)
PubMed link      E-mail link

Reference Number: 1594
McNeil BK, Sorbellini M, Grubb RL 3rd, Apolo A, Cecchi F, Athauda G, Cohen B, Giubellino A, Simpson H, Agarwal PK, Coleman J, Getzenberg RH, Netto GJ, Shih J, Linehan WM, Pinto PA, Bottaro DP Preliminary evaluation of urinary soluble Met as a biomarker for urothelial carcinoma of the bladder. J Transl Med. 12, 199 (2014)
PubMed link      E-mail link

Reference Number: 1647
Zuo RC, Apolo AB, DiGiovanna JJ, Parnes HL, Keen CM, Nanda S, Dahut WL, Cowen EW. Cutaneous adverse effects associated with the tyrosine-kinase inhibitor cabozantinib. JAMA Dermatol. 151, 170-7 (2015)
PubMed link      E-mail link

Reference Number: 1771
Dang Q, Song W, Xu D, Ma Y, Li F, Zeng J, Zhu G, Wang X, Chang LS, He D, Li L. Kaempferol suppresses bladder cancer tumor growth by inhibiting cell proliferation and inducing apoptosis. Mol Carcinog. 54, 831-40 (2015)
PubMed link      E-mail link